Date: March 19 - 21, 2026
Location: Kobe, Japan

Cellistic will be attending the JSRM-ISCT International Conference on iPSCs, 19–21 March 2026, represented by Stefan Braam, Tarran Pierfelice, and Fionn Huang, recently joined to support partnerships across Asia-Pacific from Singapore.

As the cell therapy and regenerative medicine fields advance, the need for scalable, GMP manufacturing of allogeneic, iPSC-derived therapies continues to grow. At JSRM-ISCT, we look forward to engaging with the regional ecosystem and discussing how manufacturability can be built into programs from the earliest stages.

 

 

Supporting the Development of Cell Therapies at Scale

Bringing iPSC-based therapies to the clinic requires:

  • Streamlined development from reprogramming through differentiation and expansion, with reliable gene editing strategies.
  • Robust GMP-compliant manufacturing processes
  • Consistent quality, reproducibility, and scalability

 

 

Our iPSC-Derived Therapy Solutions

  • Pulse™ platform for Cell Line Development – accelerates and de-risks GMP Master Cell Bank (MCB) generation
  • Cellistic Echo™ platforms for Differentiation & Manufacturing at scale – expertise across multiple immune and regenerative cell types (NK Cells, Tcells, Macrophages, Cardiomyocytes, Endothelial Cells, ...)
  • STAR-CRISPR™ – Cellistic's proprietary, high-efficiency gene editing technology for multiplex edits and clear IP positioning; also available for outlicensing
  • Allo Chassis™ – ready-to-use, off-the-shelf immune-cloaked iPSC lines, designed to reduce immunogenicity and accelerate early development timelines
  • Comprehensive CDMO services – end-to-end support from process development to product release, including analytical development and cell banking; expert services backed by 15 years of experience to help developers move quickly from concept to clinical readiness

 

Let's talk about your program

Meet Fionn and the team to explore how Cellistic’s integrated platforms, technologies and CDMO expertise can streamline the development and clinical readiness of your cell therapy product.

Book a meeting